Pharma Deals Review, Vol 2008, No 92 (2008)

Font Size:  Small  Medium  Large

Pfizer and Tacere to Tackle HCV with RNAi Therapeutic

Business Review Editor

Abstract


Pfizer signed a collaboration and license agreement with Tacere Pharmaceuticals for a novel RNAi-based therapeutic for the treatment of HCV worth over US$145.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.